65,437 trials
Rotator Cuff Syndrome
Primary: Percentage of Participants in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness…
Acute Graft vs Host Disease
Primary: The Number of Participants With Lower Gastrointestinal Acute Graft-Versus-Host-Disease Treatment Response Rate on Day 28 — 19; 8 Participants
Multiple Myeloma
Primary: The Maximum Tolerated Dose (MTD) of BI 836909 — 400 Microgram Per Day (μg/d)
Unilateral Cataract Extraction · Congenital Cataract
Primary: Intraoperative Pupil Diameter — 0.14; 0.20 millimeters*minutes
Lower Limb Injury
Primary: Analgesia Duration — 22.1; 25.7 Hours
Cognitive Impairment · Frail Elderly Syndrome
Primary: Delirium by Age — 75; 77 years — p=0.508
Venous Stenosis · Venous Occlusion
Primary: Number of Participants Without Any Localized or Systemic Safety Events Through 30 Days — 45 Participants
Aortic Valve Stenosis
Primary: Change in the Late-Life Function and Disability Instrument (LLFDI) Score — 53.2; 52.0; 52.9; 58.9 units on a scale
Atrophic Acne Scar
Primary: Severity of Acne Scars — 3.19; 3.10; 2.81; 2.90 score on a scale — p=<0.008
Acute Lymphoblastic Leukemia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 69 Participants
Crohn Disease
Primary: Percentage of Participants That Achieved Symptomatic Remission at Week 6 — 40; 46 Participants
Schizophrenia
Primary: Number of Subjects With Adverse Events — 161; 93; 61; 7 Participants
Femoral Neck Fractures
Primary: Number of Participants Who Needed Transfusions — 0; 5 Participants
Glial Cell Tumors · Malignant Gliomas · Glioblastoma Multiforme
Primary: 1-year Event Free Survival (EFS) — 12; 24 percentage of participants — p=< 0.05
Phantom Limb Pain · Postoperative Pain · Neuroma
Primary: Average Phantom Limb Pain (PLP) Score — 4.1; 3.1; 2.2; 3.0 score on a scale